Programme Day 2

08.30 - 08.55

How to . . .

Hall 5

  • How to relate fibrin and microbial invasion, Robert Ariens, United Kingdom
  • How to manage perioperative bleeding complications, Michael Desborough, United Kingdom
  • How to treat immune thrombocytopenia, Waleed Ghanima, Norway

Meet the Expert

Hall 5

  • Arterial thrombosis and coagulation defects, Zsuzsanna Bereczky, Hungary
  • Drug induced platelet dysfunction, Alexander Bye, United Kingdom
  • What is new in Von Willebrand disease, Jeroen Eikenboom, The Netherlands
  • Thrombotic complications during pregnancy, Catherine Bagot, United Kingdom

08.55 - 09.20

How to . . .

Hall 5

  • How to run a coagulation lab, Steve Kitchen, United Kingdom
  • How to study NETS, Kimberly Martinod, Belgium
  • How to understand the fibrin network, Nicola Mutch, United Kingdom
  • How to diagnose and manage coagulopathies in hemoglobinopathies, Rafal Pawlinski, United States
  • How to dissect the pathophysiology of TTP, Karen Vanhoorelbeke, Belgium

Meet the Expert

Hall 5

  • Platelets and inflammation, Benoit Ho-Tin-Noé, France
  • Biochemistry of Vitamin K, Leon Schurgers, The Netherlands
  • Sex and thrombosis, Astrid van Hylckama Vlieg, The Netherlands
  • Point of care tests in thrombosis and haemostasis, Dianne Kitchen, United Kingdom
  • Paradox thromboembolism – patent foramen ovale, Francis Couturaud, France

09.20 - 09.30

Short Break

09.30 - 10.30

Focus Symposium
Thrombosis and Cancer
Hall: Lomond

Moderator: Hanne Skille (Norway)

  • 9.30 – 10.00: VTE therapy in patients with Cancer, Manuel Monreal, Spain
  • 10.00 – 10.15: Platelets promote metastatic dissemination in mouse and human models in vivo and are associated with reduced survival in lung adenocarcinoma patients, Stephanie Hyslop, Australia
  • 10.15 – 10.30: The impact of second cancer on the risk of cancer associated venous thromboembolism; a Danish nationwide study, Inger Lise Gade, Denmark

Focus Symposium
Treatment of Haemophilia
Hall: Alsh

Moderator: Johannes Thaler (Austria)

  • 9.30 – 10.00: Non-substitutive treatments in Haemophilia, Michael Makris, United Kingdom
  • 10.00 – 10.15: A fully-human bispecific antibody for the treatment of hemophilia A, John Blackwood, United Kingdom
  • 10.15 – 10.30: Emicizumab demonstrates long term efficacy and tolerability in a broad population of persons with haemophilia A (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies, Michael Callaghan, United States

Focus Symposium
Translational Science
Hall: Boisdale

  • 9.30 – 10.00: Microparticles, ready for the clinics?, Françoise Dignat-George, France
  • 10.00 – 10.15: In Silico Peptide Design: from molecular mechanism to novel therapeutic treatments for inflammatory diseases, Kanin Wichapong, The Netherlands
  • 10.15 – 10.30: Targeting CXCL1-deposition on the vessel wall with a tick-derived protein, Ingrid Dijkgraaf, The Netherlands

Focus Symposium
Anticoagulant Proteins
Hall: Carron

Moderators: Tassos Petri (United Kingdom) and Thomas Kümler (Denmark)

  • 9.30 – 10.00: Protein S – at the centre of haemostatic regulation, Josefin AhnströmUnited Kingdom
  • 10.00 – 10.15: Characterisation of citrullinated TFPI and truncated TFPI constructs by PAD4 in model and plasma systems, Stella Thomassen, The Netherlands
  • 10.15 – 10.30: Molecular, biological and clinical characterization of variants affecting the C-terminal end of antithrombin, Bravo-Perez Carlos, Spain

10.30 - 11.00

Coffee Break & Poster Viewing

11.00 - 11.30

State of the Art

A dual role for platelets in fibrinolysis

Nicola Mutch

United Kingdom

Hall: Lomond

Moderator: Sabine Eichinger (Austria)

 

State of the Art

Vascular calcification

Leon Schurgers

The Netherlands

Hall: Alsh

Moderators: Pierre Morange (France) and Banne Neneth (The Netherlands)

11.30 - 12.00

State of the Art

Management in Von Willebrand disease

Jeroen Eikenboom

The Netherlands

Hall: Lomond

Moderator: Sabine Eichinger (Austria)

 

 

State of the Art

Coagulation factors crosstalk with endothelium

Pablo Garcia de Frutos

Spain

Hall: Alsh

Pierre Morange (France) and Banne Neneth (The Netherlands)

12.00 - 12.15

Short Break

12.15 - 13.15

Special Symposium (not part of main CME programme)

13.15 - 13.30

Short Break

13.30 - 14.30

Plenary Lecture

New development in Von Willebrand research

Cécile Denis

France

Hall: Lomond

Moderator: Flora Peyvandi (Italy)

14.30 - 15.15

Contact Activation
Oral Communications
Hall: Lomond

Moderators: Claire Whyte (United Kingdom) and Marco Heestermans (Germany)

  • 14.30 – 14.45: Factor XII proline rich domain is essential for contact activation, Marco Heestermans, Germany
  • 14.45 – 15.00: High molecular weight kininogen but not factor XII deficiency protects against acetaminophen-induced hepatotoxicity in mice, Rafal Pawlinski, United States
  • 15.00 – 15.15: uPA-mediated plasminogen activation is enhanced by polyphosphate, Claire Whyte, United Kingdom

Von Willebrand Disease
Oral Communications
Hall: Alsh

Moderators: Eugenia Biguzzi (Italy) and Cédric Duval (United Kingdom)

  • 14.30 – 14.45: Endothelial cells derived from induced pluripotent stem cells have the potential to model von Willebrand Disease, Matthew Sims, United Kingdom
  • 14.45 – 15.00: Acquired Von Willebrand syndrome associated with monoclonal gammopathy, Eugenia Biguzzi, Italy
  • 15.00 – 15.15: Determination of prevalence and features of main VWF synonymous variants of the CRMW database, Fanny Lassalle, France

Vessel Wall 1
Oral Communications
Hall: Boisdale

 

Moderators: Helen Mcpherson (United Kingdom) and Catherine Lemarie (France)

  • 14.30 – 14.45: TLR3 promotes venous thrombosis through neutrophil recruitment, Maria Najem, France
  • 14.45 – 15.00: CTL-2 is a VWF receptor involved in neutrophil activation, Gaia Zirka, France
  • 15.00 – 15.15: DNAse-dependent but NETs-independent pathways of thrombus formation in vivo, Estelle Carminita, France

Platelets 2
Oral Communications
Hall: Carron

 

Moderators: Joanne Dunster (United Kingdom) and Irina Zotova (Russia)

  • 14.30 – 14.45: Allelic polymorphism of platelet glycoprotein genes GPIa and GPIIb as a possible predictive marker of response to therapy in patients with primary immune thrombocytopenia, Irina Zotova, Russia
  • 14.45 – 15.00: Platelet biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis, Alessandro Ciavarella, Italy
  • 15.00 – 15.15: Effect of antiplatelet agents on bacterial induced platelet aggregation, Laurence Camoin-Jau, France

15.15 - 15.45

Coffee Break & Poster Viewing

15.45 - 17.00

Invited Integrated Symposium
Bleeding

Hall: Lomond

 

Moderators: Flora Peyvandi (Italy) and Tomas Lindahl (Sweden)

15.45 – 16.10: Immunogenicity of coagulation factors, Jan Voorberg, The Netherlands

16.10 – 16.35: Immunogenicity of monoclonal abs with a focus on Emicizumab, Gallia Levy, Italy

16.35 – 17.00: The role of rFVIIIFc in immune tolerance, Stefan Lethagen, Denark

Invited Integrated Symposium
Thrombosis

Hall: Alsh

 

Invited Integrated Symposium
Factor XIA

Hall: Boisdale

 

Moderators: Tilman Hackeng (The Netherlands) and Bérangère Joly (France)

Invited Integrated Symposium
OMICS

Hall: Carron

 

Moderators: Frits Rosendaal (The Netherlands) and Lucia Stanciakova (Slovakia)

15.45 – 16.10: Quantitative targeted mass spectrometry for measurement of coagulation factors and other plasma proteins, Yassene Mohammed, Canada/The Netherlands

16.10 – 16.35: Metabolomics, Michael Evans, United Kingdom

16.35 – 17.00: Application of metabolomics in studies of complex traits, Dennis Mook-Kanamori, The Netherlands

17.00 - 18.30

Poster Reception

 

17.30 - 18.30

19.00 - 00.00

Congress Dinner

Venue: Glasgow Science Centre (offsite) 

The congress dinner of ECTH 2019 offers a great opportunity to meet and network with other experts in an informal setting, while tasting some local specialities from Scotland. The walking dinner will take place in a unique and iconic space: Glasgow Science Centre. This beautiful building is located on the Clyde waterfront, a vibrant place where historic Glasgow meets the modern city.